Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccine immunological studies in Finland
2024-517357-27-00Phase 4Completed
- Sponsor
- Finnish Institute for Health and Welfare
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran, PHH-1V, NVX-CoV2373, ChAdOx1 nCoV-19 and 3 more in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Finnish Institute for Health and Welfare. Started Oct 2024; status: completed.
02
Drugs
tozinameranelasomeranPHH-1VNVX-CoV2373ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-517357-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517357-27-00.